Gilder Gagnon Howe & Co. LLC Trims Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Gilder Gagnon Howe & Co. LLC reduced its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 4.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 365,463 shares of the biopharmaceutical company's stock after selling 18,530 shares during the quarter. Gilder Gagnon Howe & Co. LLC owned about 0.28% of Alnylam Pharmaceuticals worth $85,997,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Larson Financial Group LLC raised its stake in shares of Alnylam Pharmaceuticals by 187.2% in the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 73 shares during the last quarter. R Squared Ltd acquired a new stake in Alnylam Pharmaceuticals in the fourth quarter valued at approximately $33,000. OFI Invest Asset Management acquired a new stake in Alnylam Pharmaceuticals in the fourth quarter valued at approximately $35,000. Versant Capital Management Inc boosted its stake in shares of Alnylam Pharmaceuticals by 77.6% in the fourth quarter. Versant Capital Management Inc now owns 190 shares of the biopharmaceutical company's stock worth $45,000 after acquiring an additional 83 shares during the last quarter. Finally, IFP Advisors Inc boosted its stake in shares of Alnylam Pharmaceuticals by 24.2% in the fourth quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company's stock worth $57,000 after acquiring an additional 47 shares during the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Stock Performance

ALNY traded up $2.34 during trading on Tuesday, hitting $257.19. The stock had a trading volume of 941,496 shares, compared to its average volume of 879,806. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. The firm has a market capitalization of $33.46 billion, a P/E ratio of -118.52 and a beta of 0.30. The company's 50-day moving average price is $247.55 and its 200 day moving average price is $255.64. Alnylam Pharmaceuticals, Inc. has a twelve month low of $143.81 and a twelve month high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). On average, equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Insider Transactions at Alnylam Pharmaceuticals

In related news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the business's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total value of $362,246.40. Following the sale, the executive vice president now directly owns 12,881 shares in the company, valued at $3,240,344.36. The trade was a 10.06 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CMO Pushkal Garg sold 1,561 shares of the firm's stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $398,320.37. Following the transaction, the chief marketing officer now directly owns 13,537 shares of the company's stock, valued at approximately $3,454,236.29. This trade represents a 10.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 7,392 shares of company stock valued at $1,875,627 in the last ninety days. 1.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Morgan Stanley reduced their price objective on Alnylam Pharmaceuticals from $284.00 to $268.00 and set an "equal weight" rating on the stock in a research report on Friday, April 11th. JPMorgan Chase & Co. raised Alnylam Pharmaceuticals from a "neutral" rating to an "overweight" rating and lifted their target price for the company from $280.00 to $328.00 in a research report on Monday, March 24th. Citigroup raised their price objective on shares of Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the company a "buy" rating in a research note on Friday, March 21st. Scotiabank raised their price objective on shares of Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the company a "sector outperform" rating in a research note on Monday, March 31st. Finally, Royal Bank of Canada lifted their price target on shares of Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the stock an "outperform" rating in a research note on Friday, March 21st. One analyst has rated the stock with a sell rating, four have given a hold rating and twenty-two have issued a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $315.58.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.